A comparison of different formulations and dosage administrations of gemfibrozil.
暂无分享，去创建一个
[1] W. Kannel,et al. Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham study. , 2020, Annals of internal medicine.
[2] J. Tuomilehto,et al. Gemfibrozil in the treatment of dyslipidaemia. A 5-year follow-up study. , 2009, Acta medica Scandinavica. Supplementum.
[3] C. Ehnholm,et al. Gemfibrozil in the treatment of dyslipidaemias in middle-aged male survivors of myocardial infarction. , 2009, Acta medica Scandinavica.
[4] V. Manninen,et al. Clinical results with gemfibrozil and background to the Helsinki Heart Study. , 1983, The American journal of cardiology.
[5] Sutherland Wh,et al. The treatment of hyperlipoproteinaemia with gemfibrozil compared with placebo and clofibrate. , 1980 .
[6] V. Manninen,et al. Gemfibrozil and Clofibrate in the Treatment of Hyperlipidæmias. A Comparative Trial , 1976, Proceedings of the Royal Society of Medicine.
[7] G. Miller,et al. PLASMA-HIGH-DENSITY-LIPOPROTEIN CONCENTRATION AND DEVELOPMENT OF ISCHÆMIC HEART-DISEASE , 1975, The Lancet.
[8] A. Børresen,et al. Effect of gemfibrozil on serum lipid levels. , 1980, Artery.